Company Presentation

Amphilix AG

Category:Emerging Biotech Company
Date:April 23, 2024
Time:13:45 – 14:00
Speaker:Guido Koch, CEO & co-founder

Company profile

Amphilix has a First-I in-Class small molecule based radioligand for the treatment of Colorectal Cancer. We differentiate from competition in the following 3 aspects::
a) new target highly expressed in Colorectal cancer cells (and other tumors) and in tumor-associated growing blood vessels
b) small molecule-based ligand has a long residence time
c) proprietary 3D linker platform enabling excellent drug properties

Follow us